Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Melanoma treatment update.

Hensin Tsao1, Arthur J Sober

  • 1Department of Dermatology, Massachusetts General Hospital, Boston, 02114, USA. htsao@partners.org

Dermatologic Clinics
|April 20, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Applications of Reflectance Confocal Microscopy in Paediatric Dermatology: A Systematic Review.

Experimental dermatology·2026
Same author

Human Genome Promise-Are We There Yet?

JAMA dermatology·2026
Same author

Geographic variation in the impact of novel melanoma therapies on mortality.

Journal of the American Academy of Dermatology·2026
Same author

Differential stability of NRAS and BRAF oncoproteins in melanoma.

The Journal of investigative dermatology·2026
Same author

Germline inactivation of tumor suppressor BAP1 is associated with white spotting.

The Journal of clinical investigation·2026
Same author

KIT-Mutant Melanoma: Understanding the Pathway to Personalized Therapy.

Cancers·2025

Targeting oncogenic mechanisms like Bcl2 and RAS/RAF pathways shows promise for metastatic melanoma treatment. Advances in understanding melanoma biology and immunology offer new therapeutic avenues for advanced disease.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Metastatic melanoma treatment has seen limited success over the past two decades, with high-dose interferon being an exception for stage III disease.
  • Recent research highlights the potential of targeting specific oncogenic mechanisms within melanoma cells.
  • Sustained Bcl2 expression contributes to apoptosis resistance, and its reduction can enhance chemosensitivity.

Purpose of the Study:

  • To explore novel therapeutic strategies for metastatic melanoma by targeting key oncogenic pathways.
  • To investigate the role of Bcl2 in melanoma progression and its potential as a therapeutic target.
  • To identify new treatment options based on genetic mutations in the RAS signaling pathway.

Main Methods:

  • Review of recent advances in melanoma biology and therapeutic approaches.

Related Experiment Videos

  • Analysis of the role of Bcl2 in apoptosis resistance and chemosensitization with dacarbazine (DTIC).
  • Identification of activating mutations in NRAS and BRAF genes for targeted therapy development.

    • Main Results:

    • Anti-sense-mediated reduction of Bcl2 levels demonstrated chemosensitization to dacarbazine (DTIC).
    • Activating mutations in NRAS and BRAF present opportunities for targeted therapies like RAS and RAF inhibitors.
    • Understanding melanoma biology and tumor immunology is crucial for developing effective treatments.

    Conclusions:

    • Disarming oncogenic mechanisms in melanoma offers a promising therapeutic strategy.
    • Targeting Bcl2 and RAS/RAF pathway mutations can lead to improved treatment outcomes for metastatic melanoma.
    • Continued research into melanoma biology and immunology is essential for advancing patient care.